Showing 1,021 - 1,040 results of 144,150 for search '(( i we decrease ) OR ( 5 ((((step decrease) OR (nn decrease))) OR (a decrease)) ))', query time: 1.59s Refine Results
  1. 1021

    Crystal structures of Triosephosphate Isomerases from <i>Taenia solium</i> and <i>Schistosoma mansoni</i> provide insights for vaccine rationale and drug design against helminth pa... by Pedro Jimenez-Sandoval (831603)

    Published 2020
    “…Surprisingly, the epitopes corresponding to the SXD/E inserts are not the ones with the greatest immunological potential. SmTPI, but not TsTPI, habors a sole solvent exposed cysteine (SmTPI-S230) and alterations in this residue decrease catalysis. …”
  2. 1022
  3. 1023
  4. 1024

    Table_1_Elevated hypertriglyceridemia and decreased gallstones in the etiological composition ratio of acute pancreatitis as affected by seasons and festivals: A two-center real-wo... by Wenhua He (5721077)

    Published 2022
    “…The composition ratio of gallstone AP in the south center was higher than that in the north center (59.5% vs. 49%), especially in summer (62.9% vs. 44.0%) and autumn (61.5% vs. 45.7%, all P<0.001).…”
  5. 1025

    Statistically significant union pathways refer to the miRNAs with a decreased expression on day 5. by Morgana Lüdtke Azevedo (15285409)

    Published 2023
    “…<p>Statistically significant union pathways refer to the miRNAs with a decreased expression on day 5.</p>…”
  6. 1026
  7. 1027
  8. 1028

    The average speed of the model (step length/step duration), <i>v</i>, vs. the phase of a perturbation pulse, <i>φ</i> for a pulse of constant amplitude and duration. by Jooeun Ahn (299192)

    Published 2013
    “…<p>When a pulse is located in a swing phase, it cannot accelerate the model, and <i>v</i> is lower than when the entire pulse is inside double stance. …”
  9. 1029

    Pharmacological Mechanism of the Non-hallucinogenic 5‑HT<sub>2A</sub> Agonist Ariadne and Analogs by Michael J. Cunningham (14267038)

    Published 2022
    “…Compared to DOM, Ariadne shows lower signaling potency and efficacy in multiple signaling pathways examined (G<sub>q</sub>, G<sub>11</sub>, and β-arrestin2) coupled to 5-HT<sub>2A</sub> receptors. We confirmed the shift in signaling for an α-propyl analog and provide a molecular docking rationale for the progressive decrease in signaling potency with the growing length of the α-substituent. …”
  10. 1030

    Pharmacological Mechanism of the Non-hallucinogenic 5‑HT<sub>2A</sub> Agonist Ariadne and Analogs by Michael J. Cunningham (14267038)

    Published 2022
    “…Compared to DOM, Ariadne shows lower signaling potency and efficacy in multiple signaling pathways examined (G<sub>q</sub>, G<sub>11</sub>, and β-arrestin2) coupled to 5-HT<sub>2A</sub> receptors. We confirmed the shift in signaling for an α-propyl analog and provide a molecular docking rationale for the progressive decrease in signaling potency with the growing length of the α-substituent. …”
  11. 1031
  12. 1032
  13. 1033
  14. 1034

    Table_1_NOTCH1 mutation associates with impaired immune response and decreased relapse-free survival in patients with resected T1-2N0 laryngeal cancer.docx by Xiao-yang Gong (13103400)

    Published 2022
    “…A total of 469 genomic alterations were detected in 211 distinct cancer-relevant genes, and the genes found to be mutated in more than five patients (>10%) included tumor protein p53 (TP53, 78.5%), FAT atypical cadherin 1 (FAT1, 26%), LDL receptor related protein 1B (LRP1B, 19%), cyclin dependent kinase inhibitor 2A (CDKN2A, 17%), tet methylcytosine dioxygenase 2 (TET2, 17%), notch receptor 1 (NOTCH1, 12%) and neuregulin 1 (NRG1, 12%). …”
  15. 1035

    Image_1_NOTCH1 mutation associates with impaired immune response and decreased relapse-free survival in patients with resected T1-2N0 laryngeal cancer.tif by Xiao-yang Gong (13103400)

    Published 2022
    “…A total of 469 genomic alterations were detected in 211 distinct cancer-relevant genes, and the genes found to be mutated in more than five patients (>10%) included tumor protein p53 (TP53, 78.5%), FAT atypical cadherin 1 (FAT1, 26%), LDL receptor related protein 1B (LRP1B, 19%), cyclin dependent kinase inhibitor 2A (CDKN2A, 17%), tet methylcytosine dioxygenase 2 (TET2, 17%), notch receptor 1 (NOTCH1, 12%) and neuregulin 1 (NRG1, 12%). …”
  16. 1036
  17. 1037
  18. 1038
  19. 1039
  20. 1040